In the Treat CTC randomized phase II trial, patients with HER2 non-amplified breast cancer and ≥1 centrally confirmed CTC/15 ml of blood were randomized (1:1) to Trastuzumab treatment. This evidence concerns the gene ERBB2 and breast cancer.